

02/20/98

JCS57 U.S. PTO

PCT  
US  
20 FEB 1998

Express Mail No.

FORM PTO-1390 (REV 10-95)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY DOCKET NUMBER  003364.P001	
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371				U.S. APPLICATION NO. (If known, see 37 CFR 1.5) <b>09/029042</b>	
INTERNATIONAL APPLICATION NO. PCT/KR96/00145		INTERNATIONAL FILING DATE August 23, 1996		PRIORITY DATE CLAIMED August 24, 1995	
TITLE OF INVENTION HETEROLOGOUS PROTEIN PRODUCTION SYSTEM USING AVIAN CELLS					
APPLICANT(S) FOR DO/EO/US Sun-Young Kim; Kee-Won Kim; Tae-Han Kim; Jeong-Ho Hwang; Seon-Hee Kim; Sun-Young Lee					
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:					
<ol style="list-style-type: none"><li>1. <input checked="" type="checkbox"/> This is a <b>FIRST</b> submission of items concerning a filing under 35 U.S.C. 371.</li><li>2. <input type="checkbox"/> This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a filing under 35 U.S.C. 371.</li><li>3. <input type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b)) and PCT articles 22 and 39(1).</li><li>4. <input type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.</li><li>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)).<ol style="list-style-type: none"><li>a. <input checked="" type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau).</li><li>b. <input type="checkbox"/> have been transmitted by the International Bureau.</li><li>c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</li></ol></li><li>6. <input type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)).</li><li>7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)).<ol style="list-style-type: none"><li>a. <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau).</li><li>b. <input type="checkbox"/> have been transmitted by the International Bureau.</li><li>c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</li><li>d. <input type="checkbox"/> have not been made and will not be made.</li></ol></li><li>8. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</li><li>9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).</li><li>10. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</li></ol>					
Items 11. to 16. below concern document(s) or information included:					
<ol style="list-style-type: none"><li>11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</li><li>12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</li><li>13. <input type="checkbox"/> A <b>FIRST</b> preliminary amendment. <input type="checkbox"/> A <b>SECOND</b> or <b>SUBSEQUENT</b> preliminary amendment.</li><li>14. <input type="checkbox"/> A subsequent specification.</li><li>15. <input type="checkbox"/> A change of power of attorney and/or address letter.</li><li>16. <input checked="" type="checkbox"/> Other items or information:  Copy of PCT Request; copy of PCT Demand; copy of correction pursuant to Invitation under article 19 of the Patent Law; copy of published International Search Report; copy of published International Preliminary Examination Report; request for priority; copy of complete application with new pages (27 pages)</li></ol>					

US

## Annex US.II, page 2 PCT Applicant's Guide - Volume II - National Chapter - US

U.S. APPLICATION NO. (if known, see 37 CFR 1.5)		INTERNATIONAL APPLICATION NO. <b>PCT/KR96/00145</b>		ATTORNEY'S DOCKET NUMBER <b>003364.P001</b>	
---	--	--	--	--	--

<b>17. <input checked="" type="checkbox"/> The following fees are submitted:</b>  <b>BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5) ):</b> Search Report has been prepared by the EPO or JPO . . . . . <b>\$880.00</b> International preliminary examination fee paid to USPTO (37 CFR 1.482) <b>\$680.00</b> No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)) . . . . . <b>\$750.00</b> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO . . . . . <b>\$1070.00</b> International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4) . . . . . <b>\$94.00</b>  <div style="text-align: right;"><b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b></div>				<b>CALCULATIONS FOR PTO USE ONLY</b>	
<div style="text-align: right;"><b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b></div>				<b>\$ 1070.00</b>	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				<b>\$</b>	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	21 - 20 =	1	X \$22.00	\$ 22.00	
Independent claims	7 - 3 =	4	X \$82.00	\$ 328.00	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$270.00	\$	
<b>TOTAL OF ABOVE CALCULATIONS =</b>				<b>\$ 1420.00</b>	
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).				<b>\$</b>	
<b>SUBTOTAL =</b>				<b>\$ 1420.00</b>	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				<b>\$</b>	
<b>TOTAL NATIONAL FEE =</b>				<b>\$ 1420.00</b>	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property				<b>\$</b>	
<b>TOTAL FEES ENCLOSED =</b>				<b>\$ 1420.00</b>	
				<b>\$ Amount to be:</b> <b>refunded</b>	<b>\$</b>
				<b>charged</b>	<b>\$</b>

a. ☒ A check in the amount of \$ 1420.00 to cover the above fees is enclosed.


b. ☐ Please charge my Deposit Account No. \_\_\_\_\_ in the amount of \$ \_\_\_\_\_ to cover the above fees.  
A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 022666. A duplicate copy of this sheet is enclosed.

**NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.**

SEND ALL CORRESPONDENCE TO:

Blakely, Sokoloff, Taylor & Zafman LLP  
 12400 Wilshire Blvd. 7th Floor  
 Los Angeles, CA 90025-1026

  
 SIGNATURE  
 Eric S. Hyman  
 NAME  
 30,139  
 REGISTRATION NUMBER

HETEROLOGOUS PROTEIN PRODUCTION SYSTEM  
USING AVIAN CELLS

BACKGROUND OF THE INVENTION

5 1. Field of the Invention

The present invention relates to novel expression systems that can produce biomedically important heterologous proteins including human erythropoietin (hereafter "EPO"), and more specifically to the production of various heterologous proteins by transfecting DNA  
10 encoding the proteins, such as the genomic DNA encoding EPO into avian cells.

2. Related Arts

Many recombinant proteins used in medicine are relatively small and simple in their structure, and biologically functional proteins can be  
15 produced in prokaryote such as *E. coli*. However, some human proteins of medical interest, such as TPA (tissue plasminogen activator), Factor VIII, EPO, etc. are more complicated because biological function requires post-translational modification. For example, EPO is extensively glycosylated with the carbohydrate portion  
20 accounting for 40 % of the molecular mass. It has been shown that the carbohydrate portion of EPO is important for biological function. Accordingly, EPO produced in *E. coli*, yeast or insect is inactive or very weakly active *in vivo*, while EPO produced in COS or CHO cells was found to be fully active. Accordingly, those kinds of heterologous  
25 proteins have been produced only in mammalian cells.

In the meantime, the avian system has been used for the study of gene expression in higher eukaryote for a long time. One of the first viruses to be linked to tumors was the *Rous sarcoma* virus of chicken,

09/029042-051598

and this virus was instrumental in demonstrating that the retroviral oncogene can originate from a cellular gene, leading to the concept of the protooncogen. Studies of gene expression have also been done using the RSV LTR promoter, which has often be used for high level  
5 expression of heterologous genes in mammalian cells. In addition, avian embryo cells have been used extensively in studies of various animal viruses.

### SUMMARY OF THE INVENTION

The present invention is a research for the high level expression  
10 of eukaryotic heterologous proteins. It is an object of the present invention to provide a novel heterologous gene expression system which can produce proteins of higher eukaryotic cells. It is another object to provide the method of efficiently producing higher eukaryotic proteins, such as EPO, etc., which has been known to be active only  
15 when they are produced in a mammalian cell. It is a further object of the invention to provide the method of producing, especially, EPO among the eukaryotic proteins described above.

To accomplish the objects of the present invention, the present invention provides a heterologous gene expression system comprising  
20 a DNA encoding a heterologous protein, a vector for receiving the DNA; and an avian cell for harboring the vector.

The present invention also provides a method of producing a heterologous protein comprising the steps of culturing the expression system of claim 1 in media to express the heterologous gene, and  
25 purifying the heterologous proteins from the cell and the media.

Preferably, the heterologous protein of the present invention is selected from the group consisting of those proteins that are known to be active only when expressed in mammalian cells (such as EPO, TPA,

09029042.051598

Factor VIII, etc.) and preferably, the vector contains a promoter selected from the group consisting of SV early promoter, major immediate early promoter of human cytomegalovirus (hereafter "HCMV MIEP") and RSV LTR, and preferably, the avian cell is selected from the group consisting of duck embryo cell (hereafter "DE"), chicken embryo fibroblast (hereafter "CEF") and quail fibrosarcoma (hereafter "QT"), more preferably QT-VC which was isolated by the inventors. QT-VC was deposited to the International Depository Authority, Korea Research Institute of Bioscience and Biotechnology Korean Collection for Type Culture, and assigned a deposit number of KCTC 0277BP on August 22, 1996. The deposited QT-VC was transfected with the expression vector containing SY-EPO cDNA as described in Fig. 8.

More preferably, the DNA encoding the heterologous protein is genomic DNA or cDNA.

Further, the present invention provides an EPO production system comprising a DNA encoding EPO, a vector for receiving the DNA, and an avian cell for harboring the vector.

Moreover, the invention provides a method of producing EPO comprising the steps of inserting a DNA encoding EPO into a vector, transfecting the vector into an avian cell, and culturing the transfected avian cell in media.

Preferably, the avian cell of the EPO production system is DE or QT, and the DNA is a genomic DNA encoding EPO, more preferably, the DNA selected from the group consisting of SY, JM, SH and HE described in Fig. 5.

Preferably, the vector has a promoter selected from the group consisting of SV early promoter, HCMV MIEP and RSV LTR.

The present invention also provides an avian cell as a host for

expressing genes encoding mammalian proteins.

Further, the present invention provides an novel EPO genomic sequence selected from the group consisting of SY, JM, SH and HE described in Fig. 5, and also provides an novel EPO amino acid  
 5 sequence selected from the group consisting of JM, SH and HE described in Fig. 6.

#### BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 shows the expression of the bacterial CAT gene in avian cells. DE and CEF cells were transfected with pRc/CMV containing  
 10 (+) or lacking (-) the CAT sequence. CAT activity was measured by determining the amount of acetylated chloramphenicol (AC) produced from  $^{14}\text{C}$ -chloramphenicol. The values shown are from one representative of more than five independent assays. For this particular experiment, 10  $\mu\text{g}$  of protein was reacted with  $^{14}\text{C}$ -  
 15 chloramphenicol for 20 min at 37 °C.

Fig. 2 shows the comparison of CAT gene expression between various cell types and between different promoters. The three promoter-CAT fusion constructs were transfected into DE, CEF, CHO-K1, and HeLa cells, and CAT activity was measured as described in  
 20 Fig. 1. S, SV40 early promoter; C, HCMV MIEP; R, RSV LTR. The values shown are from one representative of three independent assays. For this particular experiment, 10  $\mu\text{g}$  of protein was reacted with  $^{14}\text{C}$ -chloramphenicol for 30 min at 37 °C .

Fig. 3 shows the efficiency of DNA transfection in various cells.  
 25 pCMV-lacZ constructs was transfected into DE, CHO, Vero, HeLa, and 293T cells by calcium phosphate-DNA coprecipitation using the conditions used for the experiments shown in Fig. 2. Two days after transfection, cells were fixed and stained with X-gal. The number of

blue cells per 60 mm tissue culture plate was counted. The total number of cells between plates were comparable at  $1-3 \times 10^5$ . Transfection efficiency was calculated relative to DE cells.

Fig. 4 shows the schematic diagram for cloning of human EPO and construction of expression vectors. The five blocks represent the five coding regions of EPO. The first PCR was performed using primers 25 and 33. The amplified DNA fragment was cloned and subjected to a second PCR using primers 12 and 9. The wavy tale in primer 12 contains the nucleotide sequence from the first coding region.

Therefore, the second PCR generates the entire coding sequence of EPO so that the first and the second coding regions are attached to form without intron between them. Primers 12 and 9 contain HindIII linkers at their 5' ends, enabling cloning of the EPO genomic sequence into various expression vectors.

Fig. 5 is various EPO genomic DNA sequences. SY, SH, HE and JM are the EPO genomic DNA sequences cloned by the present invention, and AM and GI are the EPO genomic sequences which has been already reported. Since the intron between the first coding region and the second coding region was deleted during the cloning, the deleted intron is not shown in Fig. 5.

Fig. 6 is various EPO amino acid sequences. SY, SH, HE and JM are the EPO amino acid sequences cloned by the present invention, and AM and GI are the EPO amino acid sequences which have been already reported. The abbreviation of the amino acids are as follows:

A: alanine   R: arginine   N: asparagine   D: aspartic acid  
C: cystein   Q: glutamine   E: glutamic acid   H: histidine  
I: isoleucine   L: leucine   K: lysine   M: methionine

F: phenylalanine P: proline S: serine

T: threonine W: tryptophan Y: tyrosine V: valine

Fig. 7 shows the comparison of CAT gene expression between QT-VC and other mammalian cell lines. pCMV-CAT was transfected to QT-VC; CHO-K1, and Vero cells, and CAT activity was measured as described in Fig. 1. The transfection efficiency, as measured by X-gal staining following cotransfection with pCMV-lacZ, was reproducibly 3-5 % in all cases. For this particular experiment, 50 µg of protein were incubated with <sup>14</sup>C-chloramphenicol for one hour at 37 °C.

Fig. 8 is the typical structure of a plasmid used to express EPO in QT cells. The two types of BamHI cassettes which could express the gene for human glutamine synthetase (GS) was made. In these BamHI cassettes, the GS cDNA sequence was flanked by the poly A sequence from the bovine growth hormone gene and one of the two promoters, the partial MMTV LTR (from -220 to +15 from the RNA start site) or the 220 bp HSV tk promoter. The BamHI fragment expressing GS was inserted into the BamHI site of pCI-neo (Promega, Madison, WI, USA), resulting in a series of pIGA. The HindIII fragment of the SY-EPO cDNA sequence was cloned into the SmaI site of pIGA, generating the EPO expression vector, pIGA-EPO.

Fig. 9 shows the production of EPO by QT-N4D4. QT-N4D4 cells were grown to confluence in a 10 cm culture dish (day 0) in M-199 containing 10 % FBS and 1 mM MSX. On day 3, the EPO level was measured. The cells were then split into 1:3 and seeded onto 10 cm dishes. On day 6, the cells were again reached confluence, and the medium was replaced with 10 ml fresh medium containing 2 % (●) or 10 % (○) FBS. EPO levels were determined by ELISA (R & D system, Minnesota, USA)



Fig. 10 shows the comparison of EPO concentration in DE (●) and QT-N4D4 (○) measured by ELISA and by *in vitro* bioassay.

#### DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The inventors have explored the possibility of using avian cells as a host cell for heterologous gene expression. We have chosen to use three avian cells; two embryonic cells from chicken and duck, and a quail fibrosarcoma line. We chose to use the chicken and duck embryo cells for the following the reasons. First, these embryonic cells can easily be prepared from eggs, and they divide rapidly, undergoing many passages. Second, chicken and duck cells can be grown at large scale with relatively low costs. Third, some avian cells, such as those from chicken embryos have already been used for medical products. For example, influenza virus has been cultured in chicken eggs for the production of vaccines. Finally, the culture conditions, including media and temperature, required by avian embryo cells are virtually identical to those of mammalian cells, suggesting that the physiology of avian and mammalian cells is probably comparable.

Further, the reason of choosing a QT cell line is that various transformed cell lines have been already developed, and it is easy to handle these cell lines to construct a permanent cell line expressing a heterologous protein, and the culture conditions and media is similar to those of mammalian cells.

#### I. Cells and Plasmids

##### 1. Cells

The following Table 1 shows cells used in the experiment.

Table 1

Cells	Source
HeLa human cervical carcinoma cells	ATCC CCL2
Vero African green monkey kidney cells	ATCC CCL81
COS-7 African green monkey kidney cells transformed by wild-type T antigen of SV40	ATCC CRL1651
CHO-K1 Chinese hamster ovary cells	ATCC CCL61
NIH3T3 contacted-inhibited Swiss mouse embryo cells	ATCC CRL1651
Ad-5 transformed human embryonic kidney cells 293	ATCC CRL1651
SL-29 chicken embryo fibroblast cells	ATCC CRL1590
Duck embryo	ATCC CCL141 or prepared by the inventors
Quail fibrosarcoma line QT6	ATCC CRL1708
Quail fibrosarcoma line QT-VC	Isolated by the inventors KCTC 0277BP

All these cells except QT cell lines were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS). QT cell lines were cultured in M199 medium instead of DME. Duck embryo was either obtained from ATCC CCL 141 or prepared by trypsinization of 10- to 13- day old decapitated duck embryos. These avian cells were grown in minimum essential medium (Eagle) supplemented with non-essential amino acids and Earle's balanced salt solution containing 10 % FBS. These cells could be

maintained for approximately another 30 passages. Each medium used in this study was supplemented with 120 µg/ml penicillin G (Sigma P-3032; 1690 units per mg) and 200 µg/ml streptomycin (Sigma S-9137; 750 units per mg).

5                   2. Plasmids

To evaluate the efficiency of heterologous protein production in avian cells, pRc/RSV-CAT and pRc/CMV-CAT were constructed by inserting a HindIII CAT cassette (Pharmacia, Piscataway, NJ) into the HindIII sites of pRc/RSV and pRc/CMV (Invitrogen, San Diego, California, USA), respectively. For pSVCAT, the plasmid p918 was used, which has been already described by the inventors. For EPO expression vectors, three vectors were used. pCMV-gEPO was constructed by cloning the HindIII fragments of the EPO genomic sequence into the HindIII site of pRc/CMV. pSV-gEPO was derived by replacing the CAT sequence of pSV918 with the genomic EPO sequence. pIGA-EPO has cDNA of EPO controlled by HCMV MIEP and the genes of NEO and glutamine synthetase (hereafter "GS"). To measure the transfection efficiency, the plasmid pCMV-lacZ was constructed by inserting bacterial lacZ fragment into the HindIII site of pRc/CMV.

II. DNA Transfection and Gene Expression Assays

The inventors tested whether avian embryo cells could be used for high levels of heterologous gene expression instead of mammalian cells. Although avian embryo cells have been used to culture viruses, there was no report that heterologous proteins of higher eukaryotic cells were expressed in these cells. To carry out the study, it is necessary to develop the method of efficient transfection to avian cells. That is, to express heterologous genes in avian cells, it is required to develop

the transfection technique of DNA to target cells. At present, we could not find any reports on DNA transfection of avian embryo cells. Accordingly, the inventors have developed the technique that CEF and DE cells can readily be transfected with DNA.

5           Among the techniques available, we have chosen a method using calcium phosphate coprecipitation, because this works well for various adherent cells and can also be used for establishing permanent lines. We have tested many different conditions and found that the following procedure was optimum.

10           When cultures were 50-70% confluent in a 100 mm culture dish, a total of 10 µg DNA in HBS buffer (140 mM NaCl, 5 mM KCl, 0.75 mM Na<sub>2</sub>HP0<sub>4</sub>.2H<sub>2</sub>O, 6 mM dextrose, 25 mM HEPES) was incubated with the cells for 30 min at room temperature. 10 ml of regular media containing FBS was added and incubated for 20 hrs at 37 °C, except for  
15           CHO-K1 (8 hours). Cells were then treated with 10 ml of 100 µM chloroquine, and incubated for another 3 hours at 37 °C. After replacement with 10 ml of fresh media, the cells were grown for 1 to 2 days. Culture supernatants were collected and centrifuged at 1000 rpm for 10 min to remove cells and debris. To measure transfection  
20           efficiency, cells were transfected with pCMV-lacZ, rinsed once with PBS 3 days after transfection, fixed with 0.5 % glutaraldehyde (in PBS) for 10 min, and washed twice for 2-10 min each with 4 ml PBS containing 1 mM MgCl<sub>2</sub>. For X-gal staining, the staining solution [PBS containing 4 mM K<sub>3</sub>Fe(CN)<sub>6</sub>, 4 mM K<sub>4</sub>Fe(CN)<sub>6</sub>.3H<sub>2</sub>O, 2 mM MgCl<sub>2</sub>, and  
25           400 µg per ml X-gal (in dimethylformamide)] was added to fixed cells, and incubated at 37 °C for 4 hours overnight. When the reaction was completed, cells were washed once with PBS. Stained cells were kept in PBS.

CAT assay was carried out as follows:

Two to three days after transfection, cells were harvested, washed once with PBS, and resuspended in 0.25 M Tris-HCl (pH 7.5).

Total proteins were prepared by 4 cycles of freeze/thawing followed by  
5 heating at 65 °C for 7 min. Equivalent amounts of protein were  
assayed for CAT activity at 37 °C for 30 min. The amount of protein  
and the reaction time varied, depending on the experiments. For  
example, the CAT activity of cell extracts prepared from DE cells was  
so high that only 10 µg protein and 20 to 30 min reaction time had to be  
10 used, and under this condition, levels of CAT activity in other  
mammalian cells were very low or undetectable. When CAT activity  
became detectable in other cells, virtually all <sup>14</sup>C-chloramphenicol was  
converted. The percent conversion of <sup>14</sup>C-chloramphenicol to its  
acetylated forms was determined by cutting out regions containing  
15 unreacted and acetylated forms and quantifying the amount of  
radioactivity in each by liquid scintillation counting.

### III. Gene Expression in DE and CEF

Gene expression efficiency of DE and CEF was measured using  
CAT gene. We initially chose to use a promoter from the major  
20 immediate-early region of HCMV, because this has been shown to  
drive a high level gene expression in many different cell types. In the  
plasmid pCMV-CAT, the bacterial CAT gene is placed under the control  
of the HCMV MIEP. As a negative control, the plasmid Rc/CMV  
containing the promoter but no CAT sequence was used. These  
25 plasmids were transfected into DE and CEF cells and CAT activity was  
measured to estimate the efficiency of transfection and gene  
expression. One representative result from several independent  
transfections is shown in Fig. 1. Transfection of a control plasmid  
resulted in undetectable levels of CAT activity in both cells. However,

transfection with pCMV-CAT resulted in readily detectable levels of CAT activity in both cells. In more than five independent transfection assays, the level of CAT activity was always higher in DE cells than in CEF cells. The magnitude of difference in the level of CAT activity between the two cells ranged from 10- to 50-fold, depending on the experiment. This result indicated that avian cells were readily transfected with DNA and the heterologous genes could be efficiently expressed.

#### IV. Comparison of Levels of Gene Expression between Avian and Mammalian Cells, and between Different Promoters

We have compared the levels of gene expression between avian and mammalian cells, using three different promoters;

- (1) the SV40 early promoter, which is used during the early transcriptional phase of SV40 infection;
- (2) the HCMV MIEP, which drives the expression of IE1 and IE2 regulatory proteins, immediately after HCMV infection;
- (3) the RSV LTR from an avian retrovirus.

These promoters are known to be powerful in mammalian cells, and have often been used for high level heterologous gene expression.

These promoter-CAT fusion constructs were transfected into four different cell lines, DE, CEF, CHO-K1, and HeLa, and CAT activity measured to compare the efficiency of gene expression between promoters and between cell types. To make this comparison semi-quantitative, all transfections and CAT assays were performed at the same time and using identical conditions. One representative result of such experiments is shown in Fig. 2. Here, 10  $\mu$ g of cell extracts were incubated for 30 min in the CAT reaction. Under these

particular conditions, the levels of CAT expression driven from the three promoters were very low in CHO and HeLa cells (Fig. 2). Only after larger amounts of proteins were used for extended reaction time, was CAT activity detected. In contrast, CAT activity was readily detectable  
 5 in the avian cells (Fig. 2), except for the SV40 promoter in CEF cells. It indicated that the expression in avian cells are more effective than that in mammalian cells.

The most dramatic finding was that the HCMV MIEP was extremely powerful in DE cells. In Fig. 2, the conditions used for the  
 10 CAT reaction were chosen to generate the reasonable levels of CAT activity in other samples. When the CAT reaction was performed under limiting conditions for the protein sample prepared from DE cells transfected with pCMV-CAT (i.e., when the CAT conversion was below 50 %), the levels of CAT activity of all the other samples were virtually  
 15 undetectable. Therefore, the magnitude of difference in CAT activity between the protein sample from DE cells transfected with HCMV-CAT and those from the other transfections is at least two orders of magnitude. These results suggested that heterologous genes could be expressed very efficiently under the control of the HCMV MIEP in  
 20 DE cells.

It is possible that the high levels of CAT expression seen in DE cells could be due to efficient transfection of the cell population, rather than an ability of these cells to support strong gene expression. To distinguish these possibilities, we transfected pCMV-lacZ into DE and  
 25 various animal cells. After transfection, cells were stained with X-gal, and the number of blue cells were counted to estimate the transfection efficiency. As shown in Fig. 3, the number of stained cell was always comparable between DE and other animal cells, suggesting that the high levels of CAT expression in DE cells were due to high levels of

expression in individual cells.

### V. Cloning of human erythropoietin

To test whether DE cells could indeed be used for the expression of medically important human proteins, we have isolated the genomic DNA encoding the human EPO gene. We chose to use EPO as a model because it is a secreted protein, so we could test whether DE cells properly process secreted proteins. We also used a genomic clone of EPO instead of the cDNA, to assess whether human genes are properly spliced to produce functional mRNAs in DE cells.

DNAs for cloning of EPO were prepared with blood cells collected from four people. Human peripheral blood lymphocytes were isolated by Ficoll-Hypaque gradient centrifugation of heparin-treated blood cells. Total DNA was prepared and used for polymerase chain reaction using specific oligonucleotide primers (Fig. 4). The region around the start codon was highly GC rich, so the EPO sequence was cloned by two steps of PCR using two different pairs of primers.

To obtain the genomic DNA for EPO, total DNA was prepared by lysing human peripheral blood lymphocytes using TES (10 mM Tris-HCl pH 7.8; 1 mM EDTA; 0.7 % SDS) followed by the treatment with 400 µg/ml proteinase K at 50 °C for 1 hour, phenol:chloroform extraction, and ethanol precipitation. The polymerase chain reaction (PCR) was performed using 0.1 µg of total genomic DNA and oligonucleotide primers specific to the EPO gene.

Primer #25 (sense, 5' to 3'): GAAGCTGATAAGCTGATAACC

Primer #33 (antisense, 5' to 3'): TGTGACATCCTTAGATCTCA

The samples were amplified through 30 cycles that included the



following parameters; denaturation at 92 °C for 1 min, primer annealing at 55 °C for 1min, and primer extension at 72 °C for 1 min. The DNA fragment amplified from this reaction did not contain the first 13 nucleotides in the N-terminal region, so a second PCR was performed using the following primers (Underlined, HindIII; Outlined, start codon and stop codons, respectively). The relative position of these primers are as shown in Fig. 4. Taq DNA polymerase (POSCO Chem, Korea) and pfr polymerase (STRATGENE, California, USA) were used to amplify DNA.

Primer #12 (sense, 5' to 3'):

CAAGCTTCGGAGATGGGGTGCACGAATGTCCTGCCTGGCTGTGGC

Primer #9 (antisense, 5' to 3'):

CAAGCTTTCATCTGTCCCCTGTCCTGC

The amplified DNA from the second PCR was cloned into the pCRII (Invitrogen), from which the HindIII fragment containing the genomic sequence of EPO was inserted into various expression vectors as described above. In this experiment, the amplified DNA was placed under the control of the HCMV MIEP or SV40 early promoter, generating pCMV-gEPO and pSV-gEPO respectively. SY-EPO whose amino acid sequence is identical to that of the already known EPO is used for the expression experiments in the sections VII and VIII (See the section VI).

#### VI. Analysis of Nucleotide Sequences of Cloned EPO Genomes

Genomic structure of EPO cloned by the above method is different from the natural EPO genome *in vivo*. That is, wild type EPO genomic DNA has five coding regions and four introns between them. However, in the DNA cloned by the above method, the first coding region was fused

to the second coding region to form one coding region so that it has four coding regions and three introns (Fig. 4).

The results from the analysis of EPO gene sequences isolated from four people suggested that nucleotide sequences of EPO cloned from these region are significantly different from those of the prior two EPOs (AM-EPO and GI-EPO) (Fig. 5) at the sites of intron. Such a difference was not due to the error which occurred during DNA amplification in the process of cloning. We repeated cloning and sequencing using DNAs prepared from same individuals (but at different times) and obtained the same nucleotide sequence. As another control, we amplified the already cloned EPO under the similar conditions, and determined the nucleotide sequence. Again, we obtained the same nucleotide sequence.

Amino acid sequences of four EPO genes, together with AM and GI, are shown in Fig. 6. Amino acid sequences from AM, GI and SY are identical. However, amino acid sequences from three people (JM, SH, HE) different by two or three different amino acids from GI- and AM-EPO, suggesting that there is a polymorphisms among people. When compared with AM- or GI-EPO, HE-EPO had three different amino acids at C-terminal, SH-EPO three different amino acid over the whole polypeptide, and JM-EPO two different amino acids, one at C-terminal and the other in the middle of polypeptide (See Fig. 6). For example, while AM-EPO and GI-EPO had serine, alanine, and valine at positions 36, 100 and 170 respectively, SH-EPO had arginine, serine, and tyrosine. Further, while AM-EPO and GI-EPO had valine, lysine, and aliginine at positions 170, 177, and 191, HE-EPO had tyrosine, glutamine, and glycine. In JM-EPO, lysine and tyrosine were present at positions 54 and 170, while they were threonine and valine. These results suggested that the EPO gene has a polymorphism in amino

acids sequence as well as DNA sequence.

## VII. Expression of EPO in DE Cells

In this experiment, we compared levels of EPO expression between DE cells and other cell lines.

5 EPO expression vectors were transfected into various cells including DE, CEF, CHO, HeLa, VERO, and 293T. We have included VERO cells because they are often used for heterologous gene expression, and 293T cells which drive very high levels of gene expression, presumably due to both the high frequency of DNA  
10 transfection and the presence of potent viral transactivators such as E1A, E1B, and large T antigen. Two to three days after transfection, levels of EPO in the culture supernatants were measured by the enzyme linked immunoadsorbent assay, and transfection efficiencies were determined by staining cells adhered on the culture with X-gal.  
15 Transfection efficiency was carried out by transfection of a lacZ expression vector together with an EPO expression vector as described in the section II. One representative result of this analysis is summarized in Table 2.

Table 2

Cell	HCMV MIEP	SV40 early promoter	HCMV/SV40
293	314	17.5	18
CHO	139.4	10.4	13.5
VERO	250	10.7	23.5
NIH3T3	89	79.4	1.1
DE	4335	13.8	314.8

20

When the SV40 early promoter was used, there was little

difference in the levels of EPO between cell types. However, when the HCMV MIEP was used, DE cells produced much higher levels of EPO than any other cell lines tested. The HCMV MIEP was much more active than the SV40 early promoter in almost all the cells tested.

5 This difference was especially pronounced in DE cells, where the former produced 315 times more EPO than the latter. Among the various cell types, DE cells always produced the highest level of EPO.

CHO cells are the source of cell lines producing EPO that is currently used for human application. In this transient system, however, the  
10 level of EPO in CHO cells was at least 30-fold lower than in DE cells. Difference between DE and 293T cells was also considerable. Transfection efficiency of 293T was higher by about 30-fold than any other cells including DE cells. Moreover, 293T cells produce potent viral transcription transactivators. Nevertheless, DE produced 10-  
15 fold more EPO than 293T, suggesting that DE could drive high levels of the gene expression.

In conclusion, human EPO could efficiently be produced and secreted in DE cells and that the HCMV MIEP is the promoter of choice for driving high level heterologous gene expression in DE cells.

20 In summary, we found that DE cells could produce very high levels of bacterial and human proteins. All three promoters tested drove higher levels of gene expression in DE cells than any other cell lines used in this study. In particular, the HCMV MIEP was extremely powerful in DE cells. The high level of heterologous gene expression  
25 observed was not due to a higher number of transfected cells. It appears that DE cells properly process splicing and secretion because transfection of DE cells with an expression vector containing the EPO genomic DNA sequence produced a large quantity of EPO in the culture supernatant.

For DE cells to be used for industrial purpose, one would need to develop large-scale culture techniques for these cells. There are two possible ways. First, it may be possible to use primary cells themselves as the producer line. A large number of DE cells can easily be prepared from 10- to 13 day-old duck embryos. From one embryo, we can readily obtain  $10^9$  to  $10^{10}$  cells that can undergo at least 15 passages. Therefore, it is possible to transfect DE cells at the earliest possible stage with an expression vector followed by selection of transfected cells, which might require 4-7 passages. Even if less than 5% of the cells were transfected, a large number of transfected cells would be available, suggesting that large-scale culture of primary duck embryo cells is not impossible with primary cells. Second, it will be possible to transform duck embryo cells at an early stage, using one of the large number of well-characterized oncogenes that are available. With transformed DE cells, a producer line could be constructed, and better quality control of protein production be established. It remains to be seen whether transformed DE cells will still maintain the capability for high level gene expression. Although a number of biological questions remain to be answered, the potential of these cells for the production of various proteins warrants further investigation.

#### VIII. Heterologous Gene Expression in the Transformed Avian Cell Line

The above experiments demonstrated the great potential of DE cells as producers of heterologous proteins such as EPO. However, DE cells used in the above experiments are primary cells and stop dividing after 30-40 passages *in vitro*. Therefore, unless DE cells are transformed or special techniques are developed as described above, it is difficult to use these embryonic cells for industrial production of heterologous proteins.

In the following study, we tested whether the transformed avian cell line, namely the quail fibrosarcoma line, could be used to produce EPO. The quail fibrosarcoma line used in this study, QT-VC, was subcloned from QT6 (ATCC CRL1708). This line was derived from methylcholanthrene-induced fibrosarcoma of Japanese quail. QT-VC is different from its parental line in at least two aspects. First, QT-VC grows faster than the parental line in M199 medium containing 10% FBS used in this study. The former divided every 12-24 hours, while the doubling time of the latter was 24-36 hours. Second, the QT-VC cell looks more roundish than QT6 which generally grows in a longish form. Like its parental line, QT-VC did not grow well when it was seeded at a low density. Therefore, cells had to be split to 1/3 to 1/2 after reaching confluence for continuous culture.

#### 1. Analysis of Gene Expression in QT-VC Cells

We compared the levels of gene expression between QT-VC and mammalian cells using pCMV-CAT. We chose to use the HCMV MIEP as this promoter was shown to drive high levels of gene expression in various cell types including avian cells (See the section IV). pCMV-CAT was transfected into 3 cell lines, QT-VC, CHO-K1 and Vero. To make this comparison semi-quantitative, all transfections and CAT assays were performed at the same time and using identical conditions. Transfection efficiency was also measured by cotransfecting pCM-lacZ followed by X-gal staining. The efficiency was approximately 3 % in all cases. Under these conditions, the levels of CAT expression in QT-VC cells were always 2-3 times higher than mammalian cell lines used in this study (Fig. 7). Although the level of gene expression in QT-VC cells appears to be lower than DE cells, the quail fibrosarcoma line is at least as good as mammalian cell lines, suggesting that it could be used as a producer for heterologous

proteins.

## 2. Construction of EPO Expression Vectors for QT-VC Cells

To test whether high levels of heterologous proteins could be expressed in QT cells, we have constructed other EPO expression  
5 vectors. The basic strategy for the construction of an expression vector was as follows:

First, we chose to use the HCMV MIEP to drive expression of the heterologous gene as it had already been shown to be one of the strongest promoters in avian cells as well as mammalian cells.

10 Second, the human glutamine synthetase (GS) gene was used for amplification of the target gene. Generally, the gene of interest is amplified to augment the yield of protein by using certain selectable markers in the presence of specific chemicals. One of the best examples is the dihydrofolate reductase (DHFR) gene. It has been  
15 shown that the copy number of the heterologous gene and the level of respective protein increase as the concentration of methotrexate (MTX) in the medium is slowly increased. However, this system requires the host cell defective in the gene DHFR, so cannot be directly applied to QT cells for which such a mutant line is not yet available. For this  
20 reason, we chose to use the GS gene. In this case, the host cell line need not to be deficient for GS, because only multiple copies of the GS gene can confer resistance to methionine sulfoximine (MSX).

The overall structure of EPO expression vectors constructed for the use in QT cells is shown in Fig. 8. In this structure, the cDNA  
25 sequence for EPO is under the control of the HCMV MIEP, the bacterial Neo gene is used as the first selectable marker, and the human GS gene is also present as the second selectable marker in the same plasmid. The backbone of expression vectors used in this particular

experiment was pCI-neo (Promega, USA) which uses the HCMV MIEP and the intron from the  $\beta$ -globin genome. We have made a couple of different constructs in which the GS gene is driven by the partial MMTV LTR (from -220 to +15) or the 220 bp HSV tk promoters. In either case, the magnitude of gene amplification appears to be comparable (Data not shown). Detailed procedure and supplementary data regarding the construction of expression vectors is available upon request.

### 3. Construction of QT-VC Cells Stably Expressing EPO

To construct QT-VC cell lines constitutively expressing EPO, the cells were transfected with an EPO expression vector by a calcium phosphate coprecipitation method as described in the section II. Three days after transfection, EPO production was confirmed by EILSA and transfected cells were treated with G418 (0.8 mg/ml) and MSX (25  $\mu$ M). When G418-resistant cells were grown to confluence, cells were diluted for subcloning. Because QT-VC cells do not grow efficiently at a low cell density, cells were seeded on 10-cm culture dishes at various numbers ( $10^2$ ,  $10^3$ ,  $10^4$ ,  $10^5$  per dish). Then the colonies that grew distant from other colonies were isolated by plastic O rings and expanded onto a 96-well plate. When cells reached 70 % confluence, the EPO level was measured. Subclones that produced more than 200 U/ml were serially expanded from the 12-well to 6-well to 60 mm culture plates. When cells reached confluence on a 60 mm dish, cells were split on 6-well plates and then treated with various concentrations of MSX (100  $\mu$ M, 250  $\mu$ M, 1 mM). Using this procedure, several subclones that produced large amounts of EPO and also grew fast were selected.

One of the subclones obtained through this procedure is QT-



N4D4. As shown in Fig. 9, this subclone produced 1200 U/ml when grown for 3 days after confluence. When the cells were split to 1:3, seeded on 10 cm dishes, and allowed to grow for another 3 days, N4D4 still produced 1000 U/ml. The medium was then replaced with a fresh media containing 2 % FBS and the cells still produced 400 U/ml EPO.

These results indicated that QT cells could produce a large quantity of EPO.

In conclusion, the above experiment demonstrated the great potential of QT cells as a producer for heterologous protein.

#### IX. Biological Activity of EPO Produced in Avian Cells

EPO is heavily glycosylated and such glycosylation is required for its biological activity. For example, EPO produced in *E. coli* or yeast is inactive or very weakly active *in vivo*. To test whether EPO expressed in DE or QT cells was biologically active, we carried out an *in vitro* bioassay using spleen cells isolated from mice treated with phenylhydrazine.

EPO assay: Absolute levels of EPO production after transfection of various cells were determined by enzyme linked immunoadsorbent assay which is currently used to measure EPO levels in the human serum (R & D Systems Inc., Minnesota, USA). To measure the biological activity of EPO, *in vitro* bioassay was carried out by the method of Krystal as modified by Goldberg et al Spleen cells were taken from C57BL X C3H FI hybrid mice (Seoul National University Laboratory Animal Center) on day 3 after the second of two daily injections of phenylhydrazine (60 mg/Kg of body weight per day) and spleen cell suspensions were prepared with Lymphoprep™ (NYCOMED PHARMA AS, Oslo, Norway). The spleen cells (final concentration  $4 \times 10^6$  cells per ml) were then incubated in 24 well tissue

5

10

15

20

What is claimed is:

1. An EPO production system comprising:  
a DNA encoding EPO;  
a vector for receiving the DNA; and  
an avian cell for harboring the vector.
2. The EPO production system of claim 1, wherein the avian cell is DE or CEF or QT.
3. The EPO production system of claim 2, wherein the QT is QT-VC.
4. The EPO production system of claim 1, wherein the DNA is a genomic DNA encoding EPO.
5. The EPO production system of claim 1, wherein the DNA encoding EPO is selected from the group consisting of SY, JM, SH and HE described in Fig. 5.
6. The production system of claim 1, wherein the vector contains a promoter selected from the group consisting of SV40 early promoter, HCMV MIEP and RSV LTR.
7. A method of producing EPO comprising the steps of:  
inserting a DNA encoding an EPO into a vector;  
transfecting the vector into an avian cell; and  
culturing the transfected avian cell in media.
8. The method of claim 7, wherein the avian cell is DE or CEF or QT.
9. The method of claim 8, wherein the QT is QT-VC.
10. The method of claim 7, wherein the DNA encoding EPO is a genomic DNA.
11. The method of claim 7, wherein the DNA encoding the EPO is

selected from the group consisting of SY, JM, SH and HE described in Fig. 5.

12. The method of claim 7, wherein the vector contains a promoter selected from the group consisting of SV40 early promoter, RSV LTR and HCMV MIEP.

13. An EPO genomic sequence selected from the group consisting of SY, JM, SH and HE described in Fig. 5.

14. An EPO amino acid sequence selected from the group consisting of JM, SH and HE described in Fig. 6.

15. An avian cell as a host for expressing a gene encoding an EPO.

16. The avian cell of claim 15, wherein the avian cell is DE or CEF or QT.

17. The avian cell of claim 16, wherein the QT is QT-VC.

18. A human heterologous protein production system comprising:

a DNA encoding a human heterologous protein;

a vector for receiving the DNA; and

an avian cell for harboring the vector.

19. The human heterologous protein production system of claim 18, wherein the human heterologous protein is selected from the group consisting of TPA, Factor VIII and EPO.

20. A method of producing a human heterologous protein comprising the steps of:

inserting a DNA encoding a human heterologous protein into a vector;

transfecting the vector into an avian cell; and

culturing the transfected avian cell in media.

21. The method of claim 20, wherein the human heterologous protein is selected from the group consisting of TPA, Factor VIII and EPO.

## ABSTRACT

Heterologous protein expression system including a heterologous gene DNA such as EPO genomic DNA, a vector receiving  
5 the DNA and an avian cell, such as duck embryo or quail fibrosarcoma cell line, expressing the gene in the vector can be used to efficiently produce heterologous proteins such as EPO.

862750" 24052000 5

1/17

FIG. 1






FIG.2



09/029,042

3/17

FIG.3




24052060



09/089,042

FIG.4



09029042.051598

5/17

## FIG.5A

AM	ATGGGGGTGCACGAATGTCCTGCCTGGCTGTGGCTTCTCCTGTCCCTGCT	50
GI	ATGGGGGTGCACGAATGTCCTGCCTGGCTGTGGCTTCTCCTGTCCCTGCT	50
SY	ATGGGGGTGCACGAATGTCCTGCCTGGCTGTGGCTTCTCCTGTCCCTGCT	50
JM	ATGGGGGTGCACGAATGTCCTGCCTGGCTGTGGCTTCTCCTGTCCCTGCT	50
SH	ATGGGGGTGCACGAATGTCCTGCCTGGCTGTGGCTTCTCCTGTCCCTGCT	50
HE	ATGGGGGTGCACGAATGTCCTGCCTGGCTGTGGCTTCTCCTGTCCCTGCT	50
*****		
AM	GTCGCTCCCTCTGGGCCTCCAGTCCTGGGCGCCCCACCACGCCTCATCT	100
GI	GTCGCTCCCTCTGGGCCTCCAGTCCTGGGCGCCCCACCACGCCTCATCT	100
SY	GTCGCTCCCTCTGGGCCTCCAGTCCTGGGCGCCCCACCACGCCTCATCT	100
JM	GTCGCTCCCTCTGGGCCTCCAGTCCTGGGCGCCCCACCACGCCTCATCT	100
SH	GTCGCTCCCTCTGGGCCTCCAGTCCTGGGCGCCCCACCACGCCTCATCT	100
HE	GTCGCTCCCTCTGGGCCTCCAGTCCTGGGCGCCCCACCACGCCTCATCT	100
*****		
AM	GTGACAGCCGAGTCCTGGAGAGGTACCTCTTGGAGGCCAAGGAGGCCGAG	150
GI	GTGACAGCCGAGTCCTGGAGAGGTACCTCTTGGAGGCCAAGGAGGCCGAG	150
SY	GTGACAGCCGAGTCCTGGAGAGGTACCTCTTGGAGGCCAAGGAGGCCGAG	150
JM	GTGACAGCCGAGTCCTGGAGAGGTACCTCTTGGAGGCCAAGGAGGCCGAG	150
SH	GTGACAGCCGAGTCCTGGAGAGGTACCTCTTGGAGGCCAAGGAGGCCGAG	150
HE	GTGACAGCCGAGTCCTGGAGAGGTACCTCTTGGAGGCCAAGGAGGCCGAG	150
*****		
AM	AATATCACGGTGAGACCCCTTCCCCAGCACATTCCACAGAACTCACGCTC	200
GI	AATATCACGGTGAGACCCCTTCCCCAGCACATTCCACAGAACTCACGCTC	200
SY	AATATCACGGTGAGACCCCTTCCCCAGCACATTCCACAGAACTCACGCTC	200
JM	AATATCACGGTGAGACCCCTTCCCCAGCACATTCCACAGAACTCACGCTC	200
SH	AATATCACGGTGAGACCCCTTCCCCAGCACATTCCACAGAACTCACGCTC	200
HE	AATATCACGGTGAGACCCCTTCCCCAGCACATTCCACAGAACTCACGCTC	200
*****		

6/17

## FIG.5B

AM	AGGGCTTCAGGG-AACTCCTCCCAG-ATCCAGGAACCTGGCACTTGGTTT	248
GI	AGGGCTTCAGGG-AACTCCTCCCAG-ATCCAGGAACCTGGCACTTGGTTT	248
SY	AGGGCTTCAGGG-AACTCCTCCCAG-ATCCAGGAACCTGGCACTTGGTTT	248
JM	AGGGCTTCAGGG-AACTCCTCCCAG-ATCCAGGAACCTGGCACTTGGTTT	248
SH	AGGGCTTCAGGG-AACTCCTCCCAG-ATCCAGGAACCTGGCACTTGGTTT	248
HE	AGGGCTTCAGGG-AACTCCTCCCAG-ATCCAGGAACCTGGCACTTGGTTT	250
	*****	
AM	GGGGTGGAGTTGGGAAGCTAGACACTGCCCCCTACATAAGAATAAGTCT	298
GI	GGGGTGGAGTTGGGAAGCTAGACACTGCCCCCTACATAAGAATAAGTCT	298
SY	GGGGTGGAGTTGGGAAGCTAGACACTGCCCCCTACATAAGAATAAGTCT	298
JM	GGGGTGGAGTTGGGAAGCTAGACACTGCCCCCTACATAAGAATAAGTCT	298
SH	GGGGTGGAGTTGGGAAGCTAGACACTGCCCCCTACATAAGAATAAGTCT	298
HE	GGGGTGGAGTTGGGAAGCTAGACACTGCCCCCTACATAAGAATAAGTCT	300
	*****	
AM	GGTGGCCCCAAACCATACCTGGAACTAGGCAAGGAGCAAAGCCAGCAGA	348
GI	GGTGGCCCCAAACCATACCTGGAACTAGGCAAGGAGCAAAGCCAGCAGA	348
SY	GGTGGCCCCAAACCATACCTGGAACTAGGCAAGGAGCAAAGCCAGCAGA	348
JM	GGTGGCCCCAAACCATACCTGGAACTAGGCAAGGAGCAAAGCCAGCAGA	348
SH	GGTGGCCCCAAACCATACCTGGAACTAGGCAAGGAGCAAAGCCAGCAGA	348
HE	GGTGGCCCCAAACCATACCTGGAACTAGGCAAGGAGCAAAGCCAGCAGA	350
	*****	
AM	TCCTACGGCCTGTGGGCCAGGGCCAG-AGCCTTCAGGGACCCTTGACTCC	397
GI	TCCTACGGCCTGTGGGCCAGGGCCAG-AGCCTTCAGGGACCCTTGACTCC	395
SY	TCCTACGGCCTGTGGGCCAGGGCCAA-AGCCTTCAGGGACCCTTGACTCC	397
JM	TCCTACGGCCTGTGGGCCAGGGCCAGGAGCCTTCAGGGACCCTTGACTCC	398
SH	TCCTACGGCCTGTGGGCCAGGGCCAG-AGCCTTCAGGGACCCTTGACTCC	397
HE	TCCTACGGCCTGTGGGCCAGGGCCAA-AGCCTTCAGGGACCCTTGACTCC	399
	*****	

7/17

## FIG.5C

AM	CCGGGCTGTGTGCATTTTCAGACGGGCTGTGCTGAACACTGCAGCTTGAAT	447
GI	CCGGGCTGTGTGCATTTTCAGACGGGCTGTGCTGAACACTGCAGCTTGAAT	445
SY	CCGGGCTGTGTGCATTTTCAGACGGGCTGTGCTGAACACTGCAGCTTGAAT	447
JM	CCGGGCTGTGTGCATTTTCAGACGGGCTGTGCTGAACACTGCAGCTTGAAT	448
SH	CCGGGCTGTGTGCATTTTCAGACGGGCTGTGCTGAACACTGCAGCTTGAAT	447
HE	CCGGGCTGTGTGCATTTTCAGACGGGCTGTGCTGAACACTGCAGCTTGAAT	449

\*\*\*\*\*[\*\*\*\*\*]\*\*\*\*\*

AM	GAGAAATATCACTGTCCCAGACACCAAAGTTAATTTCTATGCCTGGAAGAG	497
GI	GAGAAATATCACTGTCCCAGACACCAAAGTTAATTTCTATGCCTGGAAGAG	495
SY	GAGAAATATCACTGTCCCAGACACCAAAGTTAATTTCTATGCCTGGAAGAG	497
JM	GAGAAATATCACTGTCCCAGACACCAAAGTTAATTTCTATGCCTGGAAGAG	498
SH	GAGAAATATCACTGTCCCAGACACCAAAGTTAATTTCTATGCCTGGAAGAG	497
HE	GAGAAATATCACTGTCCCAGACACCAAAGTTAATTTCTATGCCTGGAAGAG	499

\*\*[\*\*\*\*\*]\*\*\*\*\*

AM	GATGGAGGTGAGTTCCTTTTTTTTTTTTTCCTTTCTTTTGGAGAATCT	547
GI	GATGGAGGTGAGTTCCTTTTTTTTTTTTTCCTTTCTTTTGGAGAATCT	545
SY	GATGGAGGTGAGTTCCTTTTTTTTTTTTTCCTTTCTTTTGGAGAATCT	547
JM	GATGGAGGTGAGTTCCTTTTTTTTTTTTTCCTTTCTTTTGGAGAATCT	548
SH	GATGGAGGTGAGTTCCTTTTTTTTTTTTTCCTTTCTTTTGGAGAATCT	545
HE	GATGGAGGTGAGTTCCTTTTTTTTTTTTTCCTTTCTTTTGGAGAATCT	549

\*\*\*\*\*[\*\*\*\*\*]\*\*\*\*\*

AM	CATTTGCGAGCCTGATTTTGGATGAAAGGGAGAAATGATCGAGGGGAAAGGT	597
GI	CATTTGCGAGCCTGATTTTGGATGAAAGGGAGAAATGATCGAGGGGAAAGGT	595
SY	CATTTGCGAGCCTGATTTTGGATGAAAGGGAGAAATGATCGAGGGGAAAGGT	597
JM	CATTTGCGAGCCTGATTTTGGATGAAAGGGAGAGTGATCGAGGGGAAAGGT	598
SH	CATTTGCGAGCCTGATTTTGGATGAAAGGGAGAAATGATCGAGGGGAAAGGT	595
HE	CATTTGCGAGCCTGATTTTGGATGAAAGGGAGAAATGATCGAGGGGAAAGGT	599

\*\*\*\*\*[\*\*\*\*\*]\*\*\*\*\*

865150 24062050

8/17

## FIG.5D

AM	AAAATGGAGCAGCAGAGATGAGGCTGCCTGGGCGCAGAGGCTCACGTCTA	647
GI	AAAATGGAGCAGCAGAGATGAGGCTGCCTGGGCGCAGAGGCTCACGTCTA	645
SY	AAAATGGAGCAGCAGAGATGAGGCTGCCTGGGCGCAGAGGCTCACGTCTA	647
JM	AAAATGGAGCAGCAGAGATGAGGCTGCCTGGGCGCAGAGGCTCACGTCTA	648
SH	AAAATGGAGCAGCAGAGATGAGGCTGCCTGGGCGCAGAGGCTCACGTCTA	645
HE	AAAATGGAGCAGCAGAGATGAGGCTGCCTGGGCGCAGAGGCTCACGTCTA	649
	*****	
AM	TAATCCCAGGCTGAGATGGCCGAGATGGGAGAATTGCTTGAGCCCTGGAG	697
GI	TAATCCCAGGCTGAGATGGCCGAGATGGGAGAATTGCTTGAGCCCTGGAG	695
SY	TAATCCCAGGCTGAGATGGCCGAGATGGGAGAATTGCTTGAGCCCTGGAG	697
JM	TAATCCCAGGCTGAGATGGCCGAGATGGGAGAATTGCTTGAGCCCTGGAG	698
SH	TAATCCCAGGCTGAGATGGCCGAGATGGGAGAATTGCTTGAGCCCTGGAG	695
HE	TAATCCCAGGCTGAGATGGCCGAGATGGGAGAATTGCTTGAGCCCTGGAG	699
	*****	
AM	GTTCAGACCAACCTAGGCAGCATAGTGAGATCCCCCATCTCTACAAACAT	747
GI	GTTCAGACCAACCTAGGCAGCATAGTGAGATCCCCCATCTCTACAAACAT	747
SY	GTTCAGACCAACCTAGGCAGCATAGTGAGATCCCCCATCTCTACAAACAT	747
JM	GTTCAGACCAACCTAGGCAGCATAGTGAGATCCCCCATCTCTACAAACAT	748
SH	GTTCAGACCAACCTAGGCAGCATAGTGAGATCCCCCATCTCTACAAACAT	745
HE	GTTCAGACCAACCTAGGCAGCATAGTGAGATCCCCCATCTCTACAAACAT	749
	*****	
AM	TTAAAAAAATTAGTCAGGTGAAGTGGTGCATGGTGGTAGTCCCAGATATT	797
GI	TTAAAAAAATTAGTCAGGTGAAGTGGTGCATGGTGGTAGTCCCAGATATT	795
SY	TTAAAAAAATTAGTCAGGTGAAGTGGTGCATGGTGGTAGTCCCAGATATT	797
JM	TTAAAAAAATTAGTCAGGTGAAGTGGTGCATGGTGGTAGTCCCAGATATT	798
SH	TTAAAAAAATTAGTCAGGTGAAGTGGTGCATGGTGGTAGTCCCAGATATT	795
HE	TTAAAAAAATTAGTCAGGTGAAGTGGTGCATGGTGGTAGTCCCAGATATT	799
	*****	

9/17

## FIG.5E

AM	TGGAAAGGCTGAGGCGGGAGGATCGCTTGAGCCCAGGAATTTGAGGCTGCA	847
GI	TGGAAAGGCTGAGGCGGGAGGATCGCTTGAGCCCAGGAATTTGAGGCTGCA	845
SY	TGGATGGCTGAGGCGGGAGGATCGCTTGAGCCCAGGAATTTGAGGCTGCA	847
JM	TGGAAAGGCTGAGGCGGGAGGATCGCTTGAGCCCAGGAATTTGAGGCTGCC	848
SH	TGGAAAGGCTGAGGCGGGAGGATCGCTTGAGCCCAGGAATTTGAGGCTGCA	845
HE	TGGAAAGGCTGAGGCGGGAGGATCGCTTGAGCCCAGGAATTTGAGGCTGCA	849
	*****	
AM	GTGAGCTGTGATCACACCACTGCACCTCCAGCCTCAGTGACAGAGTGAGGC	897
GI	GTGAGCTGTGATCACACCACTGCACCTCCAGCCTCAGTGACAGAGTGAGGC	895
SY	GTGAGCTGTGATCACACCACTGCACCTCCAGCCTCAGTGACAGAGTGAGGC	897
JM	GTGAGCTGTGATCACACCACTGCACCTCCAGCCTCAGTGACAGAGTGAGGC	898
SH	GTGAGCTGTGATCACACCACTGCACCTCCAGCCTCAGTGACAGAGTGAGGC	895
HE	GTGAGCTGTGATCACACCACTGCACCTCCAGCCTCAGTGACAGAGTGAGGC	899
	*****	
AM	CCTGTCTCAAAAAAGAAAAGAAAAAGAAAAATTAATGAGGGCTGTATGGA	947
GI	CCTGTCTCAAAAAAGAAAAGAAAAAGAAAAATTAATGAGGGCTGTATGGA	945
SY	CCTGTCTCAAAAAAGAAAAGAAAAAGAAAAATTAATGAGGGCTGTATGGA	947
JM	CCTGTCTCAAAAAAGAAAAGAAAAAGAAAAATTAATGAGGGCTGTATGGA	948
SH	CCTGTCTCAAAAAAGAAAAGAAAAAGAAAAATTAATGAGGGCTGTATGGA	945
HE	CCTGTCTCAAAAAAGAAAAGAAAAAGAAAAATTAATGAGGGCTGTATGGA	949
	*****	
AM	ATACATTCATTATTCATTCACCTCACTCACTCACTCATTCATTCAATTCATT	997
GI	ATACATTCATTATTCATTCACCTCACTCACTCACTCATTCATTCAATTCATT	995
SY	ATACATTCATTATTCATTCACCTCACTCACTCACTCATTCATTCAATTCATT	997
JM	ATACATTCATTATTCATTCACCTCACTCACTCACTCATTCATTCAATTCATT	998
SH	ATACATTCATTATTCATTCACCTCACTCACTCACTCATTCATTCAATTCATT	995
HE	ATACATTCATTATTCATTCACCTCACTCACTCACTCATTCATTCAATTCATT	999
	*****	

10/17

## FIG.5F

AM CATTCAACAAGTCTTATTGCATACCTTCTGTTTGCTCAGCTTGGTGCTTG 1047  
GI CATTCAACAAGTCTTATTGCATACCTTCTGTTTGCTCAGCTTGGTGCTTG 1045  
SY CATTCAACAAGTCTTATTGCATACCTTCTGTTTGCTCAGCTTGGTGCTTG 1047  
JM CATTCAACAAGTCTTATTGCATACCTTCTGTTTGCTCAGCTTGGTGCTTG 1048  
SH CATTCAACAAGTCTTATTGCATACCTTCTGTTTGCTCAGCTTGGTGCTTG 1045  
HE CATTCAACAAGTCTTATTGCATACCTTCTGTTTGCTCAGCTTGGTGCTTG 1049  
\*\*\*\*\*

AM GGGCTGCTGAGGGGCAGGAGGGAGAGGGTGACATGGGTCACTGACTCCC 1097  
GI GGGCTGCTGAGGGGCAGGAGGGAGAGGGTGACATCCCTCAGCTGACTCCC 1095  
SY GGGCTGCTGAGGGGCAGGAGGGAGAGGGTGACATGGGTCACTGACTCCC 1097  
JM GGGCTGCTGAGGGGCAGGAGGGAGAGGGTGACATGGGTCACTGACTCCC 1098  
SH GGGCTGCTGAGGGGCAGGAGGGAGAGGGTGACATGGGTCACTGACTCCC 1095  
HE GGGCTGCTGAGGGGCAGGAGGGAGAGGGTGACATGGGTCACTGACTCCC 1099  
\*\*\*\*\*

AM AGAGTCCACTCCCTGTAGGTCGGGCAGCAGGCCGTAGAAGTCTGGCAGGG 1147  
GI AGAGTCCACTCCCTGTAGGTCGGGCAGCAGGCCGTAGAAGTCTGGCAGGG 1145  
SY AGAGTCCACTCCCTGTAGGTCGGGCAGCAGGCCGTAGAAGTCTGGCAGGG 1147  
JM AGAGTCCACTCCCTGTAGGTCGGGCAGCAGGCCGTAGAAGTCTGGCAGGG 1148  
SH AGAGTCCACTCCCTGTAGGTCGGGCAGCAGGCCGTAGAAGTCTGGCAGGG 1145  
HE AGAGTCCACTCCCTGTAGGTCGGGCAGCAGGCCGTAGAAGTCTGGCAGGG 1149  
\*\*\*\*\*

AM CCTGGCCCTGCTGTGCGAAGCTGTCTGCGGGGCCAGGCCCTGTTGGTCA 1197  
GI CCTGGCCCTGCTGTGCGAAGCTGTCTGCGGGGCCAGGCCCTGTTGGTCA 1195  
SY CCTGGCCCTGCTGTGCGAAGCTGTCTGCGGGGCCAGGCCCTGTTGGTCA 1197  
JM CCTGGCCCTGCTGTGCGAAGCTGTCTGCGGGGCCAGGCCCTGTTGGTCA 1198  
SH CCTGGCCCTGCTGTGCGAAGCTGTCTGCGGGGCCAGGCCCTGTTGGTCA 1195  
HE CCTGGCCCTGCTGTGCGAAGCTGTCTGCGGGGCCAGGCCCTGTTGGTCA 1199  
\*\*\*\*\*

11/17

## FIG.5G

AM	ACTCTTCCCAGCCGTGGGAGCCCCTGCAGCTGCATGTGGATAAAGCCGTC	1247
GI	ACTCTTCCCAGCCGTGGGAGCCCCTGCAGCTGCATGTGGATAAAGCCGTC	1245
SY	ACTCTTCCCAGCCGTGGGAGCCCCTGCAGCTGCATGTGGATAAAGCCGTC	1247
JM	ACTCTTCCCAGCCGTGGGAGCCCCTGCAGCTGCATGTGGATAAAGCCGTC	1248
SH	ACTCTTCCCAGCCGTGGGAGCCCCTGCAGCTGCATGTGGATAAAGCCGTC	1245
HE	ACTCTTCCCAGCCGTGGGAGCCCCTGCAGCTGCATGTGGATAAAGCCGTC	1249
	***[*****]	
AM	AGTGGCCTTCGCAGCCTCACCACCTCTGCTTCGGGCTCTGGGAGCCCAGGT	1297
GI	AGTGGCCTTCGCAGCCTCACCACCTCTGCTTCGGGCTCTGGGAGCCCAGGT	1295
SY	AGTGGCCTTCGCAGCCTCACCACCTCTGCTTCGGGCTCTGGGAGCCCAGGT	1297
JM	AGTGGCCTTCGCAGCCTCACCACCTCTGCTTCGGGCTCTGGGAGCCCAGGT	1298
SH	AGTGGCCTTCGCAGCCTCACCACCTCTGCTTCGGGCTCTGGGAGCCCAGGT	1295
HE	AGTGGCCTTCGCAGCCTCACCACCTCTGCTTCGGGCTCTGGGAGCCCAGGT	1299
	*****[*****]	
AM	GAGTAGGAGCGGACACTTCTGCTTGCCCTTTCTGTAAGAAGGGGAGAAGG	1347
GI	GAGTAGGAGCGGACACTTCTGCTTGCCCTTTCTGTAAGAAGGGGAGAAGG	1345
SY	GAGTAGGAGCGGACACTTCTGCTTGCCCTTTCTGTAAGAAGGGGAGAAGG	1347
JM	GAGTAGGAGCGGACACTTCTGCTTGCCCTTTCTGTAAGAAGGGGAGAAGG	1348
SH	GAGTAGGAGCGGACACTTCTGCTTGCCCTTTCTGTAAGAAGGGGAGAAGG	1345
HE	GAGTAGGAGCGGACACTTCTGCTTGCCCTTTCTGTAAGAAGGGGAGAAGG	1349
	*****[*****]	
AM	GTCTTGCTAAGGAGTACAGGAACCTGTCCGTATTCTTCCCTTTCTGTGGC	1397
GI	GTCTTGCTAAGGAGTACAGGAACCTGTCCGTATTCTTCCCTTTCTGTGGC	1395
SY	GTCTTGCTAAGGAGTACAGGAACCTGTCCGTATTCTTCCCTTTCTGTGGC	1397
JM	GTCTTGCTAAGGAGTACAGGAACCTGTCCGTATTCTTCCCTTTCTGTGGC	1398
SH	GTCTTGCTAAGGAGTACAGGAACCTGTCCGTATTCTTCCCTTTCTGTGGC	1395
HE	GTCTTGCTAAGGAGTACAGGAACCTGTCCGTATTCTTCCCTTTCTGTGGC	1399
	*****[*****]	



12/17

## FIG.5H

AM ACTGCAGCGACCTCCTGTTTTCTCCTTGGCAGAAGGAAGCCATCTCCCCT 1447  
 GI ACTGCAGCGACCTCCTGTTTTCTCCTTGGCAGAAGGAAGCCATCTCCCCT 1445  
 SY ACTGCAGCGACCTCCTGTTTTCTCCTTGGCAGAAGGAAGCCATCTCCCCT 1447  
 JM ACTGCAGCGACCTCCTGTTTTCTCCTTGGCAGAAGGAAGCCATCTCCCCT 1448  
 SH ACTGCAGCGACCTCCTGTTTTCTCCTTGGCAGAAGGAAGCCATCTCCCCT 1445  
 HE ACTGCAGCGACCTCCTGTTTTCTCCTTGGCAGAAGGAAGCCATCTCCCCT 1449  
 \*\*\*\*\*

AM CCAGATGCGGCCCTCAGCTGCTCCACTCCGAACAATCACTGCTGACACTTT 1497  
 GI CCAGATGCGGCCCTCAGCTGCTCCACTCCGAACAATCACTGCTGACACTTT 1495  
 SY CCAGATGCGGCCCTCAGCTGCTCCACTCCGAACAATCACTGCTGACACTTT 1497  
 JM CCAGATGCGGCCCTCAGCTGCTCCACTCCGAACAATCACTGCTGACACTTT 1498  
 SH CCAGATGCGGCCCTCAGCTGCTCCACTCCGAACAATCACTGCTGACACTTT 1495  
 HE CCAGATGCGGCCCTCAGCTGCTCCACTCCGAACAATCACTGCTGACACTTT 1499  
 \*\*\*\*\*

AM CCGCAAACCTCTCCGAGTCTACTCCAATTTCTCCGGGGAAAGCTGAAGC 1547  
 GI CCGCAAACCTCTCCGAGTCTACTCCAATTTCTCCGGGGAAAGCTGAAGC 1545  
 SY CCGCAAACCTCTCCGAGTCTACTCCAATTTCTCCGGGGAAAGCTGAAGC 1547  
 JM CCGCAAACCTCTCCGAGTCTACTCCAATTTCTCCGGGGAAAGCTGAAGC 1548  
 SH CCGCAAACCTCTCCGAGTCTACTCCAATTTCTCCGGGGAAAGCTGAAGC 1545  
 HE CCGCAAACCTCTCCGAGTCTACTCCAATTTCTCCGGGGAAAGCTGAAGC 1549  
 \*\*\*\*\*

AM TGTACACAGGGGAGGCCTGCAGGACAGGGGACAGATGA 1584  
 GI TGTACACAGGGGAGGCCTGCAGGACAGGGGACAGATGA 1582  
 SY TGTACACAGGGGAGGCCTGCAGGACAGGGGACAGATGA 1585  
 JM TGTACACAGGGGAGGCCTGCAGGACAGGGGACAGATGA 1585  
 SH TGTACACAGGGGAGGCCTGCAGGACAGGGGACAGATGA 1583  
 HE TGTACACAGGGGAGGCCTGCAGGACAGGGGACAGATGA 1586  
 \*\*\*\*\*

13/17

## FIG.6

AM/GI	MGVHECPAWLWLLLSLLSLPLGLPVLGAPPRLICDSRVLERYLLEAKEAE	50
SY	MGVHECPAWLWLLLSLLSLPLGLPVLGAPPRLICDSRVLERYLLEAKEAE	50
JM	MGVHECPAWLWLLLSLLSLPLGLPVLGAPPRLICDSRVLERYLLEAKEAE	50
SH	MGVHECPAWLWLLLSLLSLPLGLPVLGAPPRLICDSRVLERYLLEAKEAE	50
HE	MGVHECPAWLWLLLSLLSLPLGLPVLGAPPRLICDSRVLERYLLEAKEAE	50
*****		


AM/GI	NITITGCAEHCSLNENITVPDTKVNIFYAWKRMEVGQQAVEVWQGLALLSEA	100
SY	NITITGCAEHCSLNENITVPDTKVNIFYAWKRMEVGQQAVEVWQGLALLSEA	100
JM	NITITGCAEHCSLNENITVPDTKVNIFYAWKRMEVGQQAVEVWQGLALLSEA	100
SH	NITITGCAEHCSLNENITVPDTKVNIFYAWKRMEVGQQAVEVWQGLALLSES	100
HE	NITITGCAEHCSLNENITVPDTKVNIFYAWKRMEVGQQAVEVWQGLALLSEA	100
***		

AM/GI	VLRGQALLVNSSQPWEPLQLHVDKAVSGLRSLTTLLRALGAQKEAISPPD	150
SY	VLRGQALLVNSSQPWEPLQLHVDKAVSGLRSLTTLLRALGAQKEAISPPD	150
JM	VLRGQALLVNSSQPWEPLQLHVDKAVSGLRSLTTLLRALGAQKEAISPPD	150
SH	VLRGQALLVNSSQPWEPLQLHVDKAVSGLRSLTTLLRALGAQKEAISPPD	150
HE	VLRGQALLVNSSQPWEPLQLHVDKAVSGLRSLTTLLRALGAQKEAISPPD	150
*****		

AM/GI	AASAAPLRTITADTFRKLFVRVSNFLRGKLLKLYTGEACRTGDR	193
SY	AASAAPLRTITADTFRKLFVRVSNFLRGKLLKLYTGEACRTGDR	193
JM	AASAAPLRTITADTFRKLFVRVSNFLRGKLLKLYTGEACRTGDR	193
SH	AASAAPLRTITADTFRKLFVRVSNFLRGKLLKLYTGEACRTGDR	193
HE	AASAAPLRTITADTFRKLFVRVSNFLRGELKLYTGEACRTGDG	193
*****		


14/17

FIG. 7



15/17


FIG.8



865750 24063060

16/17


FIG.9



865450" 24052060

17/17

FIG.10





Our Ref.: 003364 P001

**DECLARATION AND POWER OF ATTORNEY FOR PATENT APPLICATION**

I, a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below, next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

**HETEROLOGOUS PROTEIN PRODUCTION SYSTEM USING AVIAN CELLS**

the specification of which

is attached hereto.

XXXwas filed on February 20, 1998 asApplication Serial No. 09/029,042

(based on PCT Application Serial No. PCT/KR96/00145 filed 8/23/96)

and was amended on \_\_\_\_\_

(if applicable)

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above. I do not know and do not believe that the same was ever known or used in the United States of America before my invention thereof, or patented or described in any printed publication in any country before my invention thereof or more than one year prior to this application, that the same was not in public use or on sale in the United States of America more than one year prior to this application, and that the invention has not been patented or made the subject of an inventor's certificate issued before the date of this application in any country foreign to the United States of America on an application filed by me or my legal representatives or assigns more than twelve months prior to this application.

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119, of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

**Prior Foreign Application(s)****Priority Claimed**

<u>(Number)</u>	<u>(Country)</u>	<u>(Day/Month/Year Filed)</u>	<u>Yes</u>	<u>No</u>
<u>(Number)</u>	<u>(Country)</u>	<u>(Day/Month/Year Filed)</u>	<u>Yes</u>	<u>No</u>

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, Section 1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

(Application Serial No.)	(Filing Date)	(Status - patented, pending, abandoned)
(Application Serial No.)	(Filing Date)	(Status - patented, pending, abandoned)
(Application Serial No.)	(Filing Date)	(Status - patented, pending, abandoned)

I hereby appoint BLAKELY SOKOLOFF TAYLOR & ZAFMAN, a firm including: Farzad E. Amini, Reg. No. P42,261; Amy M. Armstrong, Reg. No. P42,265; Aloysius T. C. AuYung, Reg. No. 35,432; William Thomas Babbitt, Reg. No. 39,591; Jordan Michael Becker, Reg. No. 39,602; Bradley J. Berezna, Reg. No. 33,474; Michael A. Bernadicon, Reg. No. 35,934; Roger W. Blakely, Jr., Reg. No. 25,831; Gregory D. Caldwell, Reg. No. 39,926; Kent M. Chen, Reg. No. 39,630; Lawrence M. Cho, Reg. No. 39,942; Yong S. Choi, Reg. No. P43,324; Thomas M. Coester, Reg. No. 39,637; Roland B. Cortes, Reg. No. 39,152; Barbara Bokanov Courtney, Reg. No. P42,442; William Donald Davis, Reg. No. 38,428; Michael Anthony DeSanctis, Reg. No. 39,957; Daniel M. De Vos, Reg. No. 37,813; Tarek N. Fahmi, Reg. No. P41,402; Richard Leon Gregory, Jr., P42,607; James Y. Go, Reg. No. 40,621; Sharmini Nathan Green, Reg. No. 41,410; Dinu Gruia, Reg. No. P42,996; David R. Halvorson, Reg. No. 33,395; Thomas A. Hassing, Reg. No. 36,159; Eric Ho, Reg. No. 39,711; Willmore F. Holbrow III, Reg. No. P41,845; George W. Hoover II, Reg. No. 32,992; Eric S. Hyman, Reg. No. 30,139; Dag H. Johansen, Reg. No. 36,172; William W. Kidd, Reg. No. 31,772; Stephen L. King, Reg. No. 19,180; Tim L. Kitchen, Reg. No. P41,900; Michael J. Mallie, Reg. No. 36,591; Paul A. Mendonsa P42,879; Darren J. Milliken, P42,004; Thinh V. Nguyen, Reg. No. P42,034; Kimberley G. Nobles, Reg. No. 38,255; Michael A. Proksch P43,021; Ronald W. Reagin, Reg. No. 20,340; Babak Redjaian, Reg. No. P42,096; James H. Salter, Reg. No. 35,668; William W. Schaal, Reg. No. 39,018; James C. Scheller, Reg. No. 31,195; Anand Sethuraman, Reg. No. P43,351; Charles E. Shemwell, Reg. No. 40,171; Maria McCormack Sobrino, Reg. No. 31,639; Stanley W. Sokoloff, Reg. No. 25,128; Allan T. Sponseller, Reg. No. 38,318; Steven R. Sponseller, Reg. No. 39,384; Geoffrey T. Staniford, P43,151; Judith A. Szepesi, Reg. No. 39,393; Vincent P. Tassinari, Reg. No. P42,179; Edwin H. Taylor, Reg. No. 25,129; George G. C. Tseng, Reg. No. 41,355; Lester J. Vincent, Reg. No. 31,460; John Patrick Ward, Reg. No. 40,216; Ben J. Yorks, Reg. No. 33,609; and Norman Zafman, Reg. No. 26,250; my attorneys; and Robert Andrew Diehl, Reg. No. P40,992; and Edwin A. Sloane, Reg. No. 34,728; my patent agents, with offices located at 12400 Wilshire Boulevard, 7th Floor, Los Angeles, California 90025, telephone (310) 207-3800, with full power of substitution and revocation, to prosecute this application and to transact all business in the Patent and Trademark Office connected herewith.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

100 Full Name of First/Sole Inventor Sun-Young KIM  
 Inventor's Signature [Signature] Date 08/05/1998  
 Residence Seoul, Republic of Korea Citizenship Republic of Korea  
 (City, State) (Country)  
 Post Office Address 3-306, Hanshin Seolae Apt., 70-1, Panpo-dong, Seocho-ku  
Seoul, 137-040 Republic of Korea



200 Full Name of Second/Joint Inventor Kee-Won KIM  
 Inventor's Signature Kee-Won Kim Date 08/05/1998  
 Residence Seoul, Republic of Korea Citizenship Republic of Korea  
 (City, State) (Country)  
 Post Office Address 77-1402, Hyundai Apt., 456, Apkueong-dong, Kangnam-ku  
Seoul, 135-110 Republic of Korea

300 Full Name of Third/Joint Inventor Tae-Han KIM  
 Inventor's Signature Tae-Han KIM Date 08/05/1998  
 Residence Kyonggi-do, Republic of Korea Citizenship Republic of Korea  
 (City, State) (Country)  
 Post Office Address 206-1503, LG Apt., 111, Jeongja-dong, Puntang-ku, Seongnam-shi,  
Kyonggi-do 463-010 Republic of Korea

400 Full Name of Fourth/Joint Inventor Jeong-Ho HWANG  
 Inventor's Signature Jeong-Ho Hwang Date 08/05/1998  
 Residence Kyonggi-do, Republic of Korea Citizenship Republic of Korea  
 (City, State) (Country)  
 Post Office Address 203-1202, Hanshin Apt., 124, Imae-dong, Puntang-ku, Seongnam-shi,  
Kyonggi-do 463-060, Republic of Korea

500 Full Name of Fifth/Joint Inventor Seon-Hee KIM  
 Inventor's Signature Seon-Hee Kim Date 08/05/1998  
 Residence Seocho-ku, Republic of Korea Citizenship Republic of Korea  
 (City, State) (Country)  
 Post Office Address 23-704, Hanshin 3rd Apt., Pangpo 2-dong  
Seocho-ku 137-042 Republic of Korea

600 Full Name of Sixth/Joint Inventor Sun-Young LEE  
 Inventor's Signature Sun-Young Lee Date 08/05/1998  
 Residence \_\_\_\_\_ Citizenship Republic of Korea  
 (City, State) (Country)  
 Post Office Address 205, Samick Hights Villa, 38-3, Karak-don, Songpa-ku  
Seoul 138-160 Republic of Korea

KRX